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a b s t r a c t
Enzymatic deamination of cytidines in DNA is an intrinsic component of antibody maturation and
retroviral resistance, but can also be a source of HIV drug resistance and cancer-causing mutations. Here,
we developed a high-throughput method based on high resolution melt (HRM) analysis called
HyperHRM that can screen genomic DNA for rare hypermutated proviral sequences and accurately
quantify the number of C-to-T or G-to-A mutations in each sequence. We demonstrate the effectiveness
of the approach by proﬁling in parallel the intensity of the DNA mutator activity of all seven human
APOBEC3 proteins on the near full-length sequence of HIV-1 and the Moloney murine leukemia virus.
Additionally, HRM was successfully used to identify hypermutated proviral sequences in peripheral blood
mononuclear cells from an HIV-1 patient. These results exemplify the effectiveness of HRM-based
approaches for hypermutation quantiﬁcation and for the detection of hypermutated DNA sequences
potentially associated with disease or retroviral drug resistance.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Deamination of cytosine (C) into uracil (U) in DNA is a potentially
mutagenic process that is fundamental to both adaptive and innate
immunity (Conticello et al., 2007). Deoxycytidine deaminases such as
the activation-induced deaminase (AID) and APOBEC3 proteins
(A3) are enzymes that extensively convert deoxycytidines in single-
stranded DNA (ssDNA) into deoxyuridines, a process called hyper-
mutation [see (Conticello, 2008) for a review]. Because human
DNA polymerases cannot distinguish U from thymidine (T) in a
DNA template, adenine (A) is usually incorporated opposite U during
DNA replication, resulting in G-to-A/C-to-T mutations. The physiolo-
gical roles of the mutator activities of AID and A3 proteins are to
promote adaptive immunity through antibody afﬁnity maturation
and innate immunity by restricting retroviral infection, respectively.
However, recent studies have established strong correlations
between the enzymatic activity of A3 proteins and antiretroviral
drug resistance (Fourati et al., 2012; Hache et al., 2006; Jern et al.,
2009; Mulder et al., 2008), and also with certain forms of cancer
(Alexandrov et al., 2013; Burns et al., 2013a, 2013b; Nik-Zainal et al.,
2012; Pavri and Nussenzweig, 2011; Roberts et al., 2013). For these
reasons, a simple, quick and high-throughput tool for detecting and
quantifying hypermutation caused by the enzymatic activities of
cytidine deaminases in both the laboratory and clinic is of signiﬁcant
interest.
Until now, current methods were mostly designed to either
screen for hypermutated sequences or conduct quantitative analyses
of mutation frequency, but not both. Direct DNA sequencing of
cloned proviral DNA is an approach whereby PCR is ﬁrst performed
on DNA isolated from an infected cell population. Amplicons are
then cloned, and a small selection of clones are analyzed by DNA
sequencing [see (Bélanger et al., 2013) for an application example].
Although this is a relatively simple approach for quantifying muta-
tions in a sequence and identifying which bases are mutated, the
method is not suited for large-scale screening purposes, is labor
intensive because it requires cloning and plasmid puriﬁcation, and
does not provide high-throughput capabilities.
Next generation sequencing (NGS) is another approach that is
occasionally used to analyze hypermutations in integrated retroviral
DNA. It can provide direct sequence information on mutated residues
and the frequency at which these mutations occur in a heteroge-
neous sample. This method, however, is very costly, must usually be
outsourced, and the data analysis is labor intensive and requires
specialized software tools. Furthermore, NGS is not a suitable
approach for hypermutation screening purposes or for routine
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hypermutation analyses in vitro. Finally, the read lengths of NGS
technologies are relatively short and are thereby not amenable for
the analysis of long contiguous stretches (49 kb) of proviral DNA as
required for near full-length single genome analyses.
For hypermutation screening purposes, there exists a very simple
and powerful technique called differential DNA denaturing PCR, or
commonly called 3D-PCR (Suspene et al., 2005b). 3D-PCR involves
performing a ﬁrst round of PCR on the gDNA extracted from a cell
population, followed by a narrow gradient PCR on a short nested
region (generally less than 300 bp). Ampliﬁcation of experimental
samples at lower melting temperatures than unmutated controls
suggests the presence of A/T-rich DNA sequences that are a hallmark
of A3-induced hypermutation. The greatest advantage of 3D-PCR over
other methods is that it can amplify very rare hypermutated
sequences in a heterogeneous sample (Suspene et al., 2011, 2005a;
Vartanian et al., 2008). However, the strength of this method is also its
weakness because it is naturally biased towards amplifying only the
most heavily hypermutated sequences. It cannot therefore provide
quantitative information on the frequency of hypermutated sequences
or the mean intensity of the mutations. Another shortcoming of the
method is that it is not amenable to high-throughput applications
because of the numerous tubes required for each experimental sample
at the gradient PCR stage. Lastly, 3D-PCR only performs well on
relatively short DNA amplicons containing high numbers of mutations.
High resolution melting (HRM) is a post-PCR method that
detects small nucleotide variations in a given DNA sequence in
comparison to a reference. Base pair variations are measured as a
function of their impact on the melting temperature of the DNA
segment (Vossen et al., 2009; Wittwer, 2009). Accordingly,
increasing the A/T content of a short DNA sequence, albeit by only
a single base pair substitution, will decrease the melting tempera-
ture of that DNA fragment. HRM relies on dyes that speciﬁcally
emit ﬂuorescence only when bound to dsDNA. HRM analysis is
performed following a quantitative PCR (qPCR) reaction by slowly
melting dye-saturated PCR amplicons. Fluorescence is then mea-
sured at regular temperature intervals until the DNA strands are
completely denatured and the ﬂuorescence level reaches back-
ground. HRM is most commonly used in single nucleotide poly-
morphism (SNP) genotyping and DNA methylation analyses (Reed
and Wittwer, 2004; Wojdacz and Dobrovic, 2007).
Here, we adapted HRM analysis combined with colony PCR and
a custom analysis algorithm to identify hypermutated DNA
sequences and directly evaluate the number of G-to-A/C-to-T
mutations, without the need for plasmid puriﬁcation or DNA
sequencing. We call this approach HyperHRM. We provide appli-
cation examples for our methods by analyzing the near full-length
genomes of both HIV-1 and MoMLV that have been individually
hypermutated by each of the seven human A3 family members.
This analysis has allowed us to identify very weakly deaminated
zones in the genomes of both viruses and to characterize the
speciﬁc deamination proﬁle of each A3 protein. Finally, we
demonstrate the effectiveness of HRM-based approaches for
identifying hypermutated proviral sequences bearing hallmarks
of A3 mutator activity in the gDNA of peripheral blood mono-
nuclear cells (PBMCs) from an HIV-1 infected patient.
Results and discussion
Here we propose two strategies that employ HRM to detect
sequences with lower melting temperatures due to C-to-T/G-to-A
transition mutations (Fig. 1A and Note S1). The ﬁrst strategy is a
direct HRM analysis performed using a single round of qPCR on the
gDNA extracted from a cell population. This method is useful for
detecting hypermutated sequences within a large pool of unmutated
sequences. The second strategy, called HyperHRM, offers more
sensitivity and resolution because sequences of interest are ﬁrst
cloned and then their HRM ﬂuorescence output is measured to
controls with known numbers of mutations using the algorithm
deﬁned in the Materials and Methods Section.
To validate the accuracy of mutation quantiﬁcation by HyperHRM,
we ﬁrst cloned eGFP-derived DNA sequences containing 1 and 8G-to-
A mutations in deﬁned segments of 100 bp to 1 kb in length (Fig. 1B
and Table S1). We then resolved the mathematical relationship
between the ﬂuorescence measurements taken during the HRM step
and the number of mutations in each DNA amplicon of increasing
length (see Materials and Methods Section). We established that
there exists a robust linear correlation between ﬂuorescence and
mutation number at the temperature that maximizes the distance
between the melting curves of the controls. R-square values above
0.94 were obtained for every DNA amplicon length tested below 1 kb
(Fig. 1B). Furthermore, the approach is also very sensitive; a single
mutation could be accurately detected in amplicons of up to 648 bp
in length, while the 900 bp amplicon had an accurate detection
limit of three mutations (Table 1). Considering that hypermutated
sequences contain, by deﬁnition, several more C-to-T/G-to-A transition
mutations than any other type of mutation, the technique is therefore
sensitive enough to identify hypermutation in amplicons up to 900 bp
in length. We then examined if HRM is sufﬁciently sensitive to serve as
an effective screening tool for detecting rare hypermutated sequences
among a majority of unmutated sequences. To investigate this, we
performed serial dilutions of plasmid DNA (containing either 1, 3 or
8 mutations) in unmutated plasmid (Fig. 1C). Our experiment shows
that ﬂuorescence was detected above background in all conditions for
dilutions up to 1/1000 (Fig. 1C and Table S3).
For comparison purposes, we challenged the sensitivity of
our HRM-based approached with that of 3D-PCR (Fig. S1)
(Suspene et al., 2005b). Here we tested the sensitivity of 3D-PCR
on amplicons of 279 bp and 648 bp in length, containing 1, 3 or 8
G-to-A mutations (Fig. S1). Although 3D-PCR was able to detect
all mutations in a short 279 bp amplicon, the method failed to
provide a positive signal when 1 or 3 mutations were present in
the larger 648 bp amplicon.
Having established that HyperHRM is both sensitive and accurate,
we next tested its high-throughput capabilities in a standard retro-
viral hypermutation assay by analyzing the DNA deamination inten-
sity of each of the seven human A3 proteins along the near full-
length (8.3 kb) proviral DNA sequence of MoMLV. We produced
MoMLV reporter virus in cells that transiently expressed one of the
seven human A3 proteins. For the mutation analysis, we designed an
approach in which the genome of MoMLV is ampliﬁed in 5 large PCR
amplicons (A–E) (Fig. 2A). HRM is then performed on nested regions
within each amplicon (R1–15) (Fig. 2B). Relative ﬂuorescence is
calculated as the difference between experimental sample DNA and
the unmutated control sequence. HRM hypermutation proﬁles
revealed that APOBEC3A (A3A) had very little activity on MoMLV,
as expected, and that APOBEC3G (A3G) displayed the highest
mutator activity on the virus.
Considering that many cell types simultaneously express
more than one A3 protein, we plotted the combined effect of all
seven A3 proteins on the virus to provide a hypothetical hyper-
mutation proﬁle if all the A3 proteins were expressed (Fig. 2C).
An intriguing result emerged with region 9 (R9), which appears to
be much less targeted for deamination by all members of the A3
family. This type of deamination pattern has been observed before
for A3G acting on HIV-1, where the dead zones were identiﬁed at
the central polypurine tract (cPPT) and LTR proximal polypurine
tract (3'PPT) of the virus (Hu et al., 2010; Suspene et al., 2006;
Wurtzer et al., 2006). Although the 3'PPT is located immediately
upstream of the 3'LTR for all retroviruses, a cPPT has never
been described for MoMLV or for retroviruses other than lenti-
viruses. Sequence analysis of MoMLV R9 reveals the presence of a
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Fig. 1. Accuracy and sensitivity of HyperHRM: (A) Flow chart for HyperHRM analysis (see Note S1 for more details). (B) Correlation between PCR amplicon length and the accuracy of
mutation number determination by HyperHRM. Plasmids containing a cloned virus-derived sequence of increasing lengths with known numbers of mutations were used for
HyperHRM analysis. The analysis was performed twice in quadruplicate. Data points represent average values. (C) Sensitivity of HyperHRM for mutation detection. Plasmids
containing a cloned eGFP-derived sequence of 648 bp in length with 1, 3 or 8 mutations were diluted at the indicated ratios with a plasmid containing the parental sequence with
no mutations (Undil.: undiluted). The analysis was performed three times in quadruplicate. Data points represent mean7standard deviation (SD).
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Table 1
Correlation between PCR amplicon length and the accuracy of mutation number determination by HyperHRM analysis.
HRM amplicon length (bp)a Mutations in control sequence determined by HyperHRM analysis Optimal temperature (1C)b R2c
0 1 3 5 6 8
100 0.0 0.8 3.6 5.7 – – 85.2 0.994
279 0.3 1.3 2.1 – 6.2 – 87.8 0.944
428 0.3 1.0 2.2 – 6.2 – 87.9 0.947
523 0.2 1.0 2.7 – – 8.1 86.6 0.996
648 0.0 1.0 3.6 – – 7.7 87.9 0.985
800 0.4 0.4 3.4 4.7 – – 89.6 0.952
900 0.5 0.4 3.2 4.9 – – 89.7 0.959
1000 1.0 0.4 6.6 5.9 – – 89.4 0.738
Results represent the average of quadruplicate values. Values in italics indicate the actual number of G-to-A mutations in the control sequence as determined by DNA
sequencing.
a All amplicons used here are located within regions R11–R13 of MoMLV proviral DNA (Fig. 2A).
b Calculated temperature at which ﬂuorescence is maximized between the melting curves of the calibration controls.
c R-square value of the standard curve.
Fig. 2. Hypermutation analysis of MoMLV proviral DNA deaminated by each of the seven human A3 proteins: (A) Schematic representation of the regions analyzed in MoMLV
proviral DNA. (B) HRM analysis performed on each of the 15 proviral regions. MoMLV was independently produced in presence of each of the seven A3 proteins.
(C) Compilation of the results from (B) illustrating the contribution of A3 proteins to the overall deamination of each proviral region. (D) Linear regression plot used to
calculate mutation numbers in R12 of MoMLV by HyperHRM. (E) HyperHRM performed on 44 clones of MoMLV region 12 (R12) deaminated by A3G. The size of each sector of
the pie chart represents the percentage of all sequences containing the indicated number of mutations.
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purine-rich patch that shares a striking resemblance with ele-
ments of the cPPT sequences from various lentiviruses (Table S4).
Functional assays are required to conﬁrm if R9 contains indeed a
bona ﬁde cPPT, or if it is simply a region with strong secondary
structures that are resistant to deamination.
We next selected a region that was highly susceptible to A3G
deamination (in this case R12), and analyzed individual sequences
by HyperHRM. The optimal temperature for performing the analysis
was identiﬁed by applying the algorithm to the melting curve
ﬂuorescence data points obtained with various controls (Fig. 2D).
Fig. 3. Hypermutation analysis of HIV-1 proviral DNA in vitro and in an HIV clinical sample: (A) Schematic representation of the regions analyzed in HIV-1ΔVif proviral DNA.
(B) HRM analysis performed on each of the 16 proviral regions individually deaminated by the seven A3 proteins. (C) Compilation of the results from (B) illustrating the
contribution of A3 proteins to the overall deamination of each proviral region. (D) HRM analysis output graph of 96 clones isolated an HIV-1 infected individual. Four
sequences with lower melting temperatures than the median value are highlighted in red and dark blue. (E) Number of G-to-A mutations in each of the 4 clones that
displayed lower melting temperatures assessed by DNA sequencing. (F) Mutation analysis of hypermutated clone ♯1 by DNA sequencing.
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We then used linear regression to quantify the number of mutations
in 44 randomly selected clones (Fig. 2E). We found that most
sequences were hypermutated, with some having up to 35 muta-
tions per 640 bp sequence. The overall average mutation rate as
measured by HyperHRM was approximately 11 mutations per kb,
which is fully consistent with a recently published report from our
group using direct DNA sequencing to measure the deamination
rate in that same region (Bélanger et al., 2013). To conﬁrm these
hypermutation levels, we also analyzed the clones using standard
DNA sequencing. Our results indicate that all the mutations were G-
to-A transitions (Fig. S2), and present within a dominant 5'-GGG-3'
local sequence consensus as read on the viral plus-strand DNA
(Table S5).
Although hypermutation has a prominent role in maintaining
host health and ﬁtness through adaptive and innate immunity,
it has been shown that A3G-induced hypermutation of HIV-1 can
give rise to drug-resistant viruses (Fourati et al., 2012; Hache et al.,
2006; Jern et al., 2009; Mulder et al., 2008). A high-throughput
assay that can quickly analyze a large number of viral quasispecies
and identify hypermutation in deﬁned viral regions could help
predict potential drug resistance in HIV patients. Here we asked
whether HRM-based approaches could be used for such a task.
As with MoMLV, we partitioned the A3-sensitive HIV-1ΔVif genome
(9.7 kb) in 5 large segments (A–E) and then further into 16 smaller
regions (Fig. 3A). We then examined the effect of all seven A3 proteins
on integrated proviral DNA using HRM (Fig. 3B). We found that, as
previously published, A3D, A3F, A3G and A3H have a very potent
mutator effect on HIV-1ΔVif (Hultquist et al., 2011). Combined
deamination proﬁles show that deamination intensity is weakest
around regions 9 and 13, which are in close proximity to the central
polypurine tract (cPPT) and LTR proximal polypurine tract (3'PPT)
respectively (Fig. 3C) (Suspene et al., 2006).
Finally, we used HRM to directly screen the gDNA of PBMCs of
an HIV-1 infected patient (Group M, subtype B). Our analysis
identiﬁed 4 clones displaying signiﬁcantly lower melting tempera-
tures than the median value of the 96 clones analyzed. DNA
sequencing revealed that proviral sequences in dark blue con-
tained 2 or 3 G-to-A mutations (Fig. 3D and E), however these
were not in a 5'-GG or 5'-GA local sequence context typical of
A3-mediated deamination (data not shown). These mutations are
most likely the result of viral reverse transcriptase error rather
than A3-mediated deamination. On the other hand, clone 1 shown
in red was heavily hypermutated (Fig. 3D and E), with almost all
mutations being G-to-A's with adjacent sequence hallmarks asso-
ciated with A3 deamination (Fig. 3F). Despite being unable to
determine the exact numbers of G-to-A transition mutations in a
HIV-1 clinical sample due to the broad genetic diversity of proviral
quasispecies, HRM can identify sequences with signiﬁcantly lower
melting temperatures that have a much higher probability of being
hypermutated. DNA sequencing can afterwards be performed on a
far smaller cohort of samples, thus reducing processing times and
costs associated with DNA sequencing.
Conclusions
Overall, HRM and HyperHRM offer important technical, practical
and ﬁnancial advantages over DNA sequencing and 3D-PCR for the
detection and quantiﬁcation of hypermutations in gDNA. We have
shown that both these techniques can be used to easily identify
hypermutated DNA sequences within a pool of unmutated sequences,
as well as DNA containing a single C-to-T/G-to-A substitution.
In addition to being a powerful screening tool, HyperHRM can also
determine with near perfect accuracy the number of these substitu-
tions in DNA amplicons of up to 900 bp in length.
By using HRM analysis, we identiﬁed regions in HIV-1 and
MoMLV proviral DNA that are preferentially targeted by each of
the seven human A3 family members. Several hundred clones
for each virus would have been required to carry out such an
experiment using standard DNA sequencing. By taking advantage
of the high-throughput efﬁciency of HRM analysis, the effect of up
to six different A3 proteins can be analyzed in parallel on a near
full-length retroviral genome in less than 2 h using a single 96-
well plate. As such, HRM lead to the identiﬁcation of a previously
undescribed region in the MoMLV genome that is infrequently
targeted by A3 proteins. Interestingly, a closer look at this region
revealed sequence similarities to the cPPT of lentiviruses. We also
show in this report how HRM can be used to identify and isolate
hypermutated sequences in an HIV-1 clinical sample. Afterwards,
sequences of interest can be individually analyzed for the presence
of speciﬁc drug-resistance mutations caused by A3 deamination.
In summary, HyperHRM is a quick, inexpensive, accurate and
high-throughput method for both the detection and quantiﬁcation
of C-to-T and G-to-A hypermutation in genomic DNA. Standard
HRM analysis is a useful tool to quickly screen for the presence
of hypermutated sequences in a pool of non-hypermutated
sequences. HyperHRM can additionally be used to accurately
quantify the number of G-to-A and C-to-T mutations in a given
DNA amplicon. The combination of these unique features suggests
that HyperHRM has the potential to make important contributions
to studies investigating the impact of A3-induced hypermutation
on host/virus interactions.
Materials and methods
Cells, viruses and A3 expression vectors
Human embryonic kidney epithelium 293T (293T) and mouse
embryonic ﬁbroblast (NIH 3T3) cells were cultured in HyClone
DMEM/High Glucose medium (Thermo Fischer Scientiﬁc) supple-
mented with 10% fetal bovine serum (FBS), 100U/ml penicillin and
100 μg/ml streptomycin (Wisent). Human T4-lymphoblastoid cells
(CEM-SS) were cultured in RPMI medium (Promega) supplemen-
ted with 10% FBS, 100U/ml penicillin and 100 μg/ml streptomycin
(Wisent). eGFP-tagged A3 and A2 expression plasmids and repli-
cative MoMLV (pMOV-eGFP) have previously been described
(Bélanger et al., 2013). HIV-1ΔVif consists of the molecular clone
NL4-3 (CXCR4 tropic; subtype B) with two non-sense mutations
introduced in the vif gene by site-directed mutagenesis (Bélanger
et al., 2013). Expression plasmid pNL4-3 was kindly provided
by the NIH AIDS Research and Reference and Reagent Program
(Catalog ♯114).
Transfections and virus production
Viruses were produced by transfecting 3105 293T cells
seeded in a 6-well plate with 800 ng of pMOV-eGFP or 500 ng of
pHIV-1ΔVif using the GeneJuice transfection reagent (EMD Milli-
pore) (Bélanger et al., 2013). Standard restriction assays on MoMLV
and HIV-1ΔVif were done by co-transfecting 80 ng or 150 ng of
expression vectors encoding for A2 or A3 cDNA at a 1:10 or 1:3
ratio in respect to pMOV-eGFP or pHIV-1ΔVif, respectively. Cells
were washed with phosphate-buffered saline (PBS) 16 h following
transfection and grown for an additional 48 h in complete DMEM
media. Virus-containing supernatants were then collected, cleared
by centrifugation and ﬁltered through 0.45 μm cartridge ﬁlters
and treated with the Dpn I endonuclease to remove possible
plasmid carry-over. Virus production was quantiﬁed and normal-
ized by enzyme-linked immunosorbent assay for p30 or p24
(QuickTiter™ ELISA Kit, Cell Biolabs Inc.)
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Infection assays and genomic DNA extractions
Target NIH 3T3 or CEM-SS cells were infected with a volume
of virus-containing supernatant yielding an MOI of 0.5 when
co-transfected with the APOBEC2 control (Bélanger et al., 2013).
Infections were carried out by spinoculation at 800 g for 1 h in
presence of 8 mg/ml of polybrene. Genomic DNA was extracted
from infected cells 24 h (MoMLV) and 48 h (HIV-1ΔVif) after
infection using the Wizard genomic DNA puriﬁcation kit (Pro-
mega) according to the manufacturer's speciﬁcations.
HIV clinical samples
Genomic DNA extracted from the PBMCs of an HIV-1-infected
patient was graciously provided by Dr. Jonathan Angel, Director of
the Ottawa Hospital HIV clinic.
Hypermutation analysis by DNA sequencing
Region 12 of MoMLV proviral DNA was ampliﬁed from the
gDNA of infected NIH 3T3 cells using the PrimeStar HS high ﬁdelity
polymerase (Takara Bio Inc.) with the corresponding primers listed
in Table S1. The reaction parameters were 92 1C for 5 min,
followed by 30 cycles (92 1C for 30 s, 55 1C for 10 s, and 72 1C for
1 min), and ﬁnally 10 min at 72 1C. Puriﬁed PCR products were
then cloned using the TOPO-Blunt cloning kit (Invitrogen) and
sequenced using M13 reverse primers (Bélanger et al., 2013).
HyperHRM analysis
HyperHRM sample preparation
Proviral DNA was ampliﬁed from the gDNA of virus-infected
cells by PCR using primer pairs for viral regions A–E (Tables S1 and
S2). Amplicons were then cloned using the TOPO-Blunt cloning kit
(Invitrogen). Colonies positive for a cloned insert were diluted in
250 μl of water, of which 8 μl were used for HRM analysis in a
96-well plate format. To generate standard curves for quantiﬁca-
tion purposes, 8 μl of 12.5 fg/μl stocks of plasmid DNA containing
deﬁned numbers of G-to-A mutations in each of the 15 (MoMLV)
or 16 (HIV-1ΔVif) viral R-regions were used.
HRM sample preparation
20 ng of gDNA (diluted to 2.5 ng/μl) isolated from virus-infected
cell lines were used directly for HRM analysis described below.
HRM sample preparation from an HIV-1 patient
100 ng of gDNA from the PBMCs of an HIV-1 infected patient
were ampliﬁed using primers HIV-Pol FWD and HIV-Pol REV
(Table S2). Amplicons were then cloned using the TOPO-Blunt
cloning kit (Invitrogen). Colonies positive for a cloned insert were
diluted in 250 μl of water, of which 8 μl were used for HRM
analysis in a 96-well plate format.
HRM analysis
Each 20 μl reaction contained 10 μL of the MeltDoctor Master
Mix (Life Technologies, Catalog ♯ 4415440), 0.6 μl (0.3 μM ﬁnal) of
each R-region primer, 8 μl of the DNA template and 0.8 μl of water.
Primer sequences for the ampliﬁcation and analysis of mutations
in MoMLV and HIV-1 proviral DNA are found in Tables S1 and S2
respectively. The conditions for qPCR were 94 1C for 2 min,
followed by 40 cycles (95 1C for 30 s, 55 1C for 45 s, and 72 1C for
1 min). qPCR ampliﬁcation was immediately followed by a melting
curve analysis in which DNA amplicons were gradually heated
from 72 1C to 95 1C and ﬂuorescence values were acquired at
0.025 1C intervals. qPCR and HRM were performed on a ViiA™ 7
real-time PCR instrument (Applied Biosystems), and data was
analyzed using the ViiA™ 7 system software (Applied Biosystems).
Bioinformatics analysis for mutation quantiﬁcation (algorithm
determination)
By systematically testing the correlation between mutation num-
bers and ﬂuorescence at different temperatures along the melting
curves, we found a strong linear relationship at the temperature at
which the relative distance between the melting curves of the
controls is maximal. To determine mutation numbers in samples,
we imported the HRM melting curve data ﬁle to a Microsoft Excel
spreadsheet and identiﬁed the temperature at which the difference
in ﬂuorescence between the controls was maximized using the
following formula: max1r jrn∑ki ¼ 1ðxi;j xiþ1;j Þ
where:
n is the total number of temperatures of the sample analyzed;
k is number of control samples to generate the standard curve;
xi;j is the amount of ﬂuorescence for curve i at temperature j.
Linear regression was then used to evaluate the number of
mutations in experimental samples as a function of the relative
ﬂuorescence at the optimal temperature using the formula
y¼ AþBx; where y is the number of mutations (dependent variable),
and x is the amount of ﬂuorescence (independent variable). The R
Statistical Software (R Development Core Team) was used to conduct
correlation analyses and Microsoft Excel was utilized for optimal
temperature identiﬁcation and regression analyses.
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